tbuckley/cabot-search huggingface dataset:
Are physical measures related to patient-centred outcomes in ARDS survivors?
Authors: Kitty S Chan, Lisa Aronson Friedman, Victor D Dinglas, Catherine L Hough, Carl Shanholtz, E Wesley Ely, Peter E Morris, Pedro A Mendez-Tellez, James C Jackson, Ramona O Hopkins, Dale M Needham
Journal: Thorax (2017)

<h3>Objective</h3> To inform selection of physical measures for studies of acute respiratory distress syndrome (ARDS) survivors within 12 months of ARDS. <h3>Methods</h3> Secondary analysis of data from 6-month survivors participating in a US multicentre prospective study (ARDSNet Long-Term Outcome Study, N=134) or a multisite prospective study in Baltimore, Maryland, USA (Improving Care of Acute Lung Injury Patients, N=99). Physical measures, assessed at 6-month follow-up, were categorised according to the WHO9s International Classification of Disability and Health: body functions and structures, activity and participation. Patient-centred outcomes were evaluated at 6 and 12 months: survival, hospitalisation, alive at home status and health-related quality of life. Pearson correlation, linear and logistic regression models were used to quantify associations of physical measures with patient-centred outcomes. <h3>Main results</h3> No 6-month body functions and structures measure demonstrated consistent association with 6-month or 12-month outcomes in multivariable regression. The 6 min walk test, an activity measure, was associated with 6-month Short-Form 36 (SF-36) physical component scores (PCS, β range: 0.99 to 1.52, p&lt;0.05). Participation measures (Functional Performance Inventory, FPI; Instrumental Activities of Daily Living, IADLs) were associated with SF-36 PCS (β range: FPI, 1.51–1.52; IADL, −1.88 to −1.32; all p&lt;0.05) and Euro-QOL-5D utility score (β range: FPI, 2.00–3.67; IADL, −2.89 to −2.50; all p&lt;0.01) at 6 and 12 months. <h3>Conclusions</h3> Participation measures better reflect patient9s quality of life than measures of body functions and structures within 12 months of ARDS among 6-month survivors, and are recommended for inclusion as a core measure in future studies.
Intensified CHOP with Rituximab for Intermediate or High-Risk Non-Hodgkin’s Lymphoma: Interim Analysis of a Randomized Phase III Trial in Elderly Patients by the Dutch HOVON and Nordic Lymphoma Groups.
Authors: Pieter Sonneveld, Wim van Putten, Harald Holte, Douwe Biesma, Marinus van Marwijk-Kooy, Mark Kramer, Pierre Wijermans, Monique Steijaert, Peter Huijgens, Mikael Eriksson
Journal: Blood (2005)
Impact of G-CSF for Outcomes of Non-M3 AML Patients Who Were Treated By Anthracycline-Based Induction (7+3 regimen) Chemotherapies
Authors: Ka-Won Kang, Yong Park, Dae Sik Kim, Se Ryeon Lee, Hwa Jung Sung, Seok Jin Kim, Chul Won Choi, Byung Soo Kim
Journal: Blood (2015)
A fifth of healthcare spending is wasted, says OECD report
Authors: Matthew Limb
Journal: BMJ (2017)

Health economists have estimated that a fifth of spending on healthcare in countries of the Organisation for Economic Co-operation and Development is ineffective and have issued a call for action.

They highlighted wide variation between countries in spending on hospital care, drugs, and administration and urged policy makers to use budgets more effectively. “The evidence of waste in healthcare is indisputable. Now is the time to act upon it,” said the OECD’s report.1

Agnes Couffinhal, a senior OECD health economist and the report’s main author, said, “At a time when public budgets are under pressure worldwide, it is alarming that around one fifth of health expenditure makes no or minimal contribution to good health outcomes.”

The study does not calculate how much each of the 35 OECD countries is wasting on healthcare. Rather, it …
Surgical Management of Adolescents and Young Adults With Gastrointestinal Stromal Tumors
Authors: Katherine E. Fero, Taylor M. Coe, Paul T. Fanta, Chih-Min Tang, James D. Murphy, Jason K. Sicklick
Journal: JAMA Surgery (2017)

There is a dearth of population-based evidence regarding outcomes of the adolescent and young adult (AYA) population with gastrointestinal stromal tumors (GISTs).To describe a large cohort of AYA patients with GISTs and investigate the effect of surgery on GIST-specific survival (GSS) and overall survival (OS).This retrospective cohort study of 392 AYA patients and 5373 older adult (OA) patients in the Surveillance, Epidemiology, and End Results (SEER) database with GISTs histologically diagnosed from January 1, 2001, through December 31, 2013, with follow-up through December 31, 2015, compared the baseline characteristics of AYA (13-39 years old) and OA (≥40 years old) patients and among AYA patients stratified by operative management. Kaplan-Meier estimates were used for OS analyses. Cumulative incidence functions were used for GSS analysis. The effect of surgery on survival was evaluated with a multivariable Fine-Gray regression model.Tumor resection.GIST-specific survival and OS.This study included 392 AYA and 5373 OA patients diagnosed with GISTs (207 [52.8%] male AYA patients, 2767 [51.5%] male OA patients, 277 [70.7%] white AYA patients, and 3661 [68.1%] white OA patients). Compared with the OA patients, more AYA patients had small-intestine GISTs (139 [35.5%] vs 1465 [27.3%], P = .008) and were managed operatively (332 [84.7%] vs 4212 [78.4%], P = .003). Multivariable analysis of AYA patients found that nonoperative management was associated with a more than 2-fold increased risk of death from GISTs (subdistribution hazard ratio, 2.27; 95% CI, 1.21-2.25; P = .01). On subset analysis of 349 AYA patients with tumors of the stomach and small intestine, small-intestine location was associated with improved survival (OS: 91.1% vs 77.2%, P = .01; GSS: 91.8% vs 78.0%, P = .008). On subset analysis of 91 AYA patients with metastatic disease, operative management was associated with improved survival (OS: 69.5% vs 53.7%, P = .04; GSS: 71.5% vs 56.7%, P = .03).This study found that AYA patients are more likely to undergo surgical management than OA patients. Operative management is associated with improved OS and GSS in AYA patients, including those with metastatic disease.
Differences In DNA Damage Response Pathways In the PBMCs of Patients with MGUS, Asymptomatic Myeloma and Symptomatic Multiple Myeloma
Authors: Vassilis L. Souliotis, Maria Gkotzamanidou, Petros P. Sfikakis, Evangelos Terpos, Soterios A. Kyrtopoulos, Meletios A. Dimopoulos
Journal: Blood (2010)
Impact of achievement of complete cytogenetic response on outcome in patients with myelodysplastic syndromes treated with hypomethylating agents
Authors: Elias Jabbour, Paolo Strati, Monica Cabrero, Susan O'Brien, Farhad Ravandi, Carlos Bueso‐Ramos, Qiao Wei, Jianhua Hu, Simon Abi Aad, Nicholas J. Short, Courtney Dinardo, Naval Daver, Tapan Kadia, William Wierda, Yue Wei, Simona Colla, Gautam Borthakur, Jorge Cortes, Zeev Estrov, Hagop Kantarjian, Guillermo Garcia‐Manero
Journal: American Journal of Hematology (2017)

Two hundred and sixteen consecutive patients with MDS and abnormal karyotype treated with hypomethylating agents between 4/04 and 10/12 were reviewed. Median follow-up was 17 months. Using IWG criteria, best responses were complete response (CR) in 79 patients (37%), partial response (PR) in 4 (2%), and hematologic improvement (HI) in 10 (5%). Cytogenetic response (CyR) was achieved in 78 patients (36%): complete (CCyR) in 62 (29%) and partial in 16 (7%). CyR was achieved in 48 of 79 patients (61%) with CR, 1 of 14 (7%) with PR/HI, and in 29 of the 123 (24%) with no morphologic response. Median overall survival (OS) and leukemia-free survival (LFS) for patients with and without CCyR were 21 and 13 months (P = .007), and 16 and 9 months (P = .001), respectively. By multivariate analysis, the achievement of CCyR was predictive for better OS (HR = 2.1; P < .001). In conclusion, CyR occurs at a rate of 36% (complete in 29%) in patients with MDS treated with HMA and is not always associated with morphological response. The achievement of CCyR is associated with survival improvement and constitutes a major predictive factor for outcome particularly in patients without morphologic response. Therefore, the achievement of CCyR should be considered a milestone in the management of patients with MDS.
Bortezomib Inhibits the Survival and Proliferation of Bone Marrow Stromal Cells Via Downregulation of the Chemokine CXCL12
Authors: Ha-Yon Kim, Yoon-Suk Oh, Ik-Chan Song, Hyo-Jin Lee, Hwan-Jung Yun, Samyong Kim, Deog-Yeon Jo
Journal: Blood (2012)
Aspirin and Aspirin Combined with Low-Molecular-Weight Heparin in Women with Unexplained Recurrent Miscarriage: a Randomized Controlled Multicenter Trial (ALIFE Study).
Authors: Stef P. Kaandorp, Mariëtte Goddijn, Joris A.M. van der Post, Barbara A. Hutten, Harold R. Verhoeve, Karly Hamulyak, Ben-Willem Mol, Nienke Folkeringa, Marleen Nahuis, Dimitri Papatsonis, Harry R. Buller, Fulco van der Veen, Saskia Middeldorp
Journal: Blood (2009)
Tosedostat Plus Low Dose Cytarabine Induces a High Rate of Responses That Can be Predicted By Genetic Profiling in Elderly AML
Authors: Giuseppe Visani, Federica Loscocco, Fabio Fuligni, Eliana Zuffa, Alberto Sensi, Alfonso Zaccaria, Gerardo Musuraca, Barbara Giannini, Alessandro Lucchesi, Francesca Fabbri, Anna Maria Mianulli, Patrizia Tosi, Michela Tonelli, Anna Candoni, Renato Fanin, Giovanni Sparaventi, Marco Gobbi, Marino Clavio, Marco Rocchi, Pier Paolo Piccaluga, Alessandro Isidori
Journal: Blood (2015)
The Leukemia-Associated Antigen PRAME Is Overexpressed in Myeloid Leukemias and Inhibits Cell Differentiation by Blocking the Receptor for Retinoic Acid (RAR)-Signaling in Vitro and Is Therefore a Interesting Candidate for Targeted Immunotherapies.
Authors: Jochen Greiner, Lars Bullinger, Krzysztof Giannopoulos, Anita Schmitt, Marlies Goetz, Lena Kienle, Hartmut Döhner, Michael Schmitt
Journal: Blood (2008)
6 Year Experience of Treatment by Imatinib in CML CP Patientsin 6 Million Population Region of Russia(Saint-Petersburg and Leningrad region)with Impact On Time and Kind of Pretreatment.
Authors: Kudrat Abdulkadirov, Elza Lomaia, Vasiliy Shuvaev, Alla Abdulkadirova, Vera Udalieva, Elena Usacheva, Elena Machulaitene, Irina Zotova, Ekaterina Poznyak, Elena Koryagina, Natalia Ilina, Tatiana Shneider, Svetlana Stepanova, Ekaterina Romanova, Eugenia Salamatova, Elena Goryunova, Natalija Lazorko, Irina Martinkevich, Andrey Zaritskey
Journal: Blood (2009)
Natural History of AML / MDS Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) Using Reduced Intensity (RIC) Preparative Regimens.
Authors: Betul Oran, Sergio Giralt, Munir Shahjahan, Athanasios Anagnostopoulos, Daniel Couriel, Partow Kebriaei, Chitra Hosing, Shubhra Ghosh, Ernesto de Meis, Michele Donato, Touch Ativivas, Antonio Carrasco-Yalan, Richard Champlin, Marcos de Lima
Journal: Blood (2005)
Gastrointestinal Stromal Tumor Showing Intense Tracer Uptake on PSMA PET/CT
Authors: Benjamin Noto, Matthias Weckesser, Boris Buerke, Michaela Pixberg, Nemanja Avramovic
Journal: Clinical Nuclear Medicine (2017)

A 70-year-old man with suspected prostate cancer was referred for 68Ga-PSMA-HBED-CC PET/CT (short PSMA PET/CT) for staging of tumor extent. Apart from vivid tracer uptake in the prostate gland and osseous metastasis, PSMA PET/CT revealed a large soft tissue mass with calcifications in the left upper abdomen showing intense tracer uptake. Histologic examination revealed the mass to be a gastrointestinal stromal tumor.
A Phase II Study of Oral Panobinostat (LBH589) for Chronic Phase Chronic Myeloid Leukemia (CML) with Resistance to ≥2 BCR-ABL Tyrosine Kinase Inhibitors
Authors: Andrey Zaritskey, Giuliana Alimena, Lech Konopka, Jila Shamsazar, Priscille M. Bourquelot, Muhammad Jalaluddin, Martha Li, Anna Turkina, Gert J. Ossenkoppele, Stuart L. Goldberg, Bayard Powell
Journal: Blood (2008)
Correlation between Classic Driver Oncogene Mutations in EGFR , ALK , or ROS1 and 22C3–PD-L1 ≥50% Expression in Lung Adenocarcinoma
Authors: Deepa Rangachari, Paul A. VanderLaan, Meghan Shea, Xiuning Le, Mark S. Huberman, Susumu S. Kobayashi, Daniel B. Costa
Journal: Journal of Thoracic Oncology (2017)
Antithymocyte Globulin (ATG), Cyclosporine (CyA), and Danazol Versus ATG and CyA As Treatment for Children with Aplastic Anemia: Result of Matched-Pair Analysis
Authors: Kazuko Kudo, Ryoji Kobayashi, Yoshiyuki Kosaka, Masahiro Tsuchida, Hideo Mugishima, Akira Ohara, Hiroshi Yagasaki, Hiromasa Yabe, Akira Morimoto, Yoshiyuki Takahashi, Shouichi Ohga, Tatsutoshi Nakahata, Seiji Kojima
Journal: Blood (2011)
Detection of Herpesvirus and Adenovirus Infections in Patients Undergoing Stem Cell Transplantation: Looking Below the Tip of the Iceberg with the Microarray Technology.
Authors: Anette Ditzen, Markus Stichling, Rene Mueller, Anke Rutzka, Kristine Hille, Thomas Illmer, Martin Bornhaeuser, Gerhard Ehninger, Enno Jacobs, Ralf Ehricht, Jacques Rohayem
Journal: Blood (2007)
Cisplatin-Based Protocols as Salvage Therapy for Relapsed or Refractory Hodgkin’s Lymphoma Patients.
Authors: Iván Alvarez, Anna Sureda, Reyes Arranz, Raúl Córdoba, Blanca Xicoy, Blanca Sánchez, María Teresa Bernal, María Isabel G. Roncero, Edelmira Martí, Alberto Pliego, Pascual Fernández-Abellán, Josep María Ribera, Jose María Fernández-Rañada, Jorge Sierra
Journal: Blood (2005)
Neutrophil - Lymphocyte Ratio (NLR) at Diagnosis Is an Independent Prognostic Factor in Patients with Nodular Sclerosis Hodgkin Lymphoma: Results of a Large Multicenter Study Involving 990 Patients
Authors: Alessia Bari, Luigi Marcheselli, Tamar Tadmor, Raffaella Marcheselli, Maria Christina Cox, Samantha Pozzi, Angela Ferrari, Luca Baldini, Paolo Gobbi, Massimo Federico, Aaron Polliack, Stefano Sacchi
Journal: Blood (2015)
Somatic Ephrin Receptor Mutations Are Associated with Metastasis in Primary Colorectal Cancer
Authors: Lucy Mathot, Snehangshu Kundu, Viktor Ljungström, Jessica Svedlund, Lotte Moens, Tom Adlerteg, Elin Falk-Sörqvist, Verónica Rendo, Claudia Bellomo, Markus Mayrhofer, Carme Cortina, Magnus Sundström, Patrick Micke, Johan Botling, Anders Isaksson, Aristidis Moustakas, Eduard Batlle, Helgi Birgisson, Bengt Glimelius, Mats Nilsson, Tobias Sjöblom
Journal: Cancer Research (2017)

The contribution of somatic mutations to metastasis of colorectal cancers is currently unknown. To find mutations involved in the colorectal cancer metastatic process, we performed deep mutational analysis of 676 genes in 107 stages II to IV primary colorectal cancer, of which half had metastasized. The mutation prevalence in the ephrin (EPH) family of tyrosine kinase receptors was 10-fold higher in primary tumors of metastatic colorectal than in nonmetastatic cases and preferentially occurred in stage III and IV tumors. Mutational analyses in situ confirmed expression of mutant EPH receptors. To enable functional studies of EPHB1 mutations, we demonstrated that DLD-1 colorectal cancer cells expressing EPHB1 form aggregates upon coculture with ephrin B1 expressing cells. When mutations in the fibronectin type III and kinase domains of EPHB1 were compared with wild-type EPHB1 in DLD-1 colorectal cancer cells, they decreased ephrin B1-induced compartmentalization. These observations provide a mechanistic link between EPHB receptor mutations and metastasis in colorectal cancer. Cancer Res; 77(7); 1730-40. ©2017 AACR.
Melanoma in congenital melanocytic naevi
Authors: V.A. Kinsler, P. O'Hare, N. Bulstrode, J.E. Calonje, W.K. Chong, D. Hargrave, T. Jacques, D. Lomas, N.J. Sebire, O. Slater
Journal: British Journal of Dermatology (2017)

Congenital melanocytic naevi (CMN) are a known risk factor for melanoma, with the greatest risk currently thought to be in childhood. There has been controversy over the years about the incidence of melanoma, and therefore over the clinical management of CMN, due partly to the difficulties of histological diagnosis and partly to publishing bias towards cases of malignancy. Large cohort studies have demonstrated that melanoma risk in childhood is related to the severity of the congenital phenotype. New understanding of the genetics of CMN offers the possibility of improvement in diagnosis of melanoma, identification of those at highest risk, and new treatment options. We review the world literature and our centre's experience over the last 25 years, including the molecular characteristics of melanoma in these patients and new melanoma incidence and outcome data from our prospective cohort. Management strategies are proposed for presentation of suspected melanoma of the skin and the central nervous system in patients with CMN, including use of oral mitogen‐activated protein kinase kinase inhibitors in NRAS‐mutated tumours.
Role of Hypoxia and Hypoxia-Inducible-Factor 1α (HIF1A) In the BM Microenvironment-Mediated Protection of Leukemic Cells.
Authors: Rodrigo Jacamo, Juliana Benito, Olga Frolova, Ye Chen, Hongbo Lu, Marina Konopleva, Michael Andreeff
Journal: Blood (2010)
Outcomes of Patients (pts) with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Treated with Hyper-CVAD-Based Chemotherapy Regimens: MD Anderson Case Series
Authors: Naveen Pemmaraju, Deborah A. Thomas, Hagop M. Kantarjian, Sherry Pierce, Susan O’Brien, Jorge E. Cortes, Stefan Faderl
Journal: Blood (2011)
Drug errors are most common cause of child safety incidents in community care, study finds
Authors: Susan Mayor
Journal: BMJ (2017)

Drug errors are the most common cause of patient care safety incidents involving children, a study of community based care provided in England and Wales has found.1

The UK has one of the highest child mortality rates in western Europe, but there is a lack of evidence to show what factors are the main contributors. Primary care provides the initial healthcare for many sick children, so the new study looked at the nature and severity of safety incidents involving children to identify areas for improvement.

Researchers analysed reports of 20 118 patient …
Optimaization of Imatinib Therapy by Combination. 5 Year Survival and Response Results of the Pilot Phase of the Randomized German CML STUDY IV.
Authors: Nadine Pletsch, Susanne Saussele, Michael Lauseker, Armin Leitner, Susanne Jung-Munkwitz, Samina Shazi, Claudia Haferlach, Brigitte Schlegelberger, Martin C Müller, Thomas Schenk, Susanne Schnittger, Markus Pfirrmann, Gerhard Ehninger, Thomas Fischer, Dieter K. Hossfeld, Hans-Jochem Kolb, Stefan W Krause, Christoph Nerl, Hans Pralle, Alois Gratwohl, Andreas Tobler, Hermann Heimpel, Leopold Balleisen, Hermann Einsele, Anthony D. Ho, Christine Falge, Mathias Hänel, Michael Pfreundschuh, Lothar Kanz, Frank Stegelmann, Claus-Henning Köhne, Stephan Kremers, Karsten Spiekermann, Wolfgang E Berdel, Cornelius F. Waller, Martin Bentz, Joerg Hasford, Andreas Hochhaus, Rüdiger Hehlmann
Journal: Blood (2009)
Resistance to Complement Dependent Cytotoxicity in CLL Cells From Patients Treated with Ofatumumab
Authors: Nisar A. Baig, Ronald P. Taylor, Margaret A. Lindorfer, Amy K Church, Betsy R. LaPlant, Emily S. Pavey, Tait D. Shanafelt, Timothy G. Call, Neil Kay, Grzegorz S. Nowakowski, Clive S. Zent
Journal: Blood (2011)
Regulation of p27 by S-Phase Kinase- Associated Protein 2 Is Associated with Aggressiveness in Diffuse Large B Cell Lymphoma (DLBCL)
Authors: Ritsuko Seki, Koichi Ohshima, Tomoaki Fujisaki, Naokuni Uike, Fumio Kawano, Hisashi Gondo, Shigeyoshi Makino, Tetsuya Eto, Yukiyoshi Moriuchi, Fumihiro Taguchi, Tomohiko Kamimura, Hiroyuki Tsuda, Ryosuke Ogawa, Kazuya Shimoda, Takashi Okamura
Journal: Blood (2008)
Bortezomib - A Potential Therapeutic Approach in B Chronic Lymphocytic Leukaemia.
Authors: A. Sarmento-Ribeiro, M. Dourado, C. Gonçalves, C. Geraldes, E. Cortesão, L. Rito, I. Sousa, R. Afonso, A. Paiva, A. Pereira, F. Guedes, L. Pais, A. Teixeira, C. Oliveira
Journal: Blood (2005)
Adoptive Transfer of mRNA-Transfected T Cells Redirected against Diabetogenic CD8 T Cells Can Prevent Diabetes
Authors: Sigal Fishman, Mark D. Lewis, L. Khai Siew, Evy De Leenheer, Dimitri Kakabadse, Joanne Davies, Doron Ziv, Alon Margalit, Nathan Karin, Gideon Gross, F. Susan Wong
Journal: Molecular Therapy (2017)
<i>SDHD</i>Promoter Mutations Ablate GABP Transcription Factor Binding in Melanoma
Authors: Tongwu Zhang, Mai Xu, Matthew M. Makowski, Christine Lee, Michael Kovacs, Jun Fang, Esther Willems, Jeffrey M. Trent, Nicholas K. Hayward, Michiel Vermeulen, Kevin M. Brown
Journal: Cancer Research (2017)

SDHD encodes subunit D of the succinate dehydrogenase complex, an integral membrane protein. Across cancer types, recurrent SDHD promoter mutations were reported to occur exclusively in melanomas, at a frequency of 4% to 5%. These mutations are predicted to disrupt consensus ETS transcription factor-binding sites and are correlated with both reduced SDHD gene expression and poor prognosis. However, the consequence of these mutations on SDHD expression in melanoma is still unclear. Here, we found that expression of SDHD in melanoma correlated with the expression of multiple ETS transcription factors, particularly in SDHD promoter wild-type samples. Consistent with the predicted loss of ETS transcription factor binding, we observed that recurrent hotspot mutations resulted in decreased luciferase activity in reporter assays. Furthermore, we demonstrated specific GABPA and GABPB1 binding to probes containing the wild-type promoter sequences, with binding disrupted by the SDHD hotspot promoter mutations in both quantitative mass spectrometry and band-shift experiments. Finally, using siRNA-mediated knockdown across multiple melanoma cell lines, we determined that loss of GABPA resulted in reduced SDHD expression at both RNA and protein levels. These data are consistent with a key role for GABPA/B1 as the critical ETS transcription factors deregulating SDHD expression in the context of highly recurrent promoter mutations in melanoma and warrant a detailed search for other recurrent promoter mutations that create or disrupt GABPA consensus sequences. Cancer Res; 77(7); 1649-61. ©2017 AACR.
Targeting Heme Oxygenase-1 Improves Poor Therapeutical Outcomes of BCR-ABL-Positive Adult B-Allwithikaros Isoform 6
Authors: Jishi Wang, Ziming Wang, Xiaojing Lin, Qin Fang, Shuya Chen, Jun Huang, Nana Zhe, Meisheng Yu, Yaming Zhang, Bingfeng Zhou
Journal: Blood (2015)
FTY720 Restores PP2A Tumor Suppressor Activity in Polycythemia Vera CD34+ Progenitors Through Inhibition of Jak2 V617F- and PI-3Kγ-Dependent SET Serine Phosphorylation and Enhancement of NOS-Dependent PP2A Tyrosine Nitration
Authors: Joshua J Oaks, A. Mukhopadhyay, Ramasamy Santhanam, S. A Saddoughi, Paolo Neviani, Jason G Harb, Besim Ogretmen, Robert Bittman, Ross L Levine, Alfonso Quintás-Cardama, Guido Marcucci, Danilo Perrotti
Journal: Blood (2011)
Follicular lymphoma grade 3B includes three cytogenetically defined subgroups with primary t(14;18), 3q27 or other translocations : t(14;18) and 3q27 are mutually exclusive.
Authors: E van den Berg, A Bosga-Bouwer, GW van Imhoff, R Boonstra, AY van der Veen, E Haralamabieva, A van den Berg, B de Jong, [No Value] Krause, MC Palmer, P Kluin, S Poppema
Journal: Leukemia (2003)